Insulet Corp.

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Insulet Corp.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Frequently asked questions
To buy Insulet Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Insulet Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Insulet Corp. is PODD:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Insulet Corp. has its primary listing on NASDAQ. You can trade Insulet Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Insulet Corp. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Insulet Corp. as part of a broader investment portfolio.